|
DT-109
- 英文名称：DT-109
- 品牌：WYTSCI
- 产地：进口
- 型号：1MG
- 货号：WT-AY-B11593
- cas：14857-82-0
- 价格： ￥1/mg
- 发布日期： 2025-04-10
- 更新日期： 2025-05-23
产品详请
| 产地 | 进口 |
| 品牌 | WYTSCI |
| 货号 | WT-AY-B11593 |
| 用途 | 科研检测 |
| 英文名称 | DT-109 |
| 包装规格 | 1MG |
| CAS编号 | 14857-82-0 |
| 别名 | DT-109 |
| 纯度 | 98+% |
| 分子式 | |
| 是否进口 | 是 |
纯度:>98% by TLC;NMR (Conforms)
分子式:C10H19N3O4
分子量:245.26
溶剂:DMSO (25 mg/ml, with warming) Water (25 mg/ml)
性状:White solid
存储:-20°C
Activity (short version):Induces glutathione biosynthesis
Function / Pharmacology:Glycine-containing peptide which has been demonstrated to ameliorate nonalcoholic fatty liver disease (NAFLD). It improved body composition, and lowered circulating glucose, lipids, transaminases, proinflammatory cytokines and steatohepatitis in mice with established NASH.1 It dose-dependently attenuates NASH and fibrosis in mice as well as in nonhuman primates.2 It induced glutathione biosynthesis in mononuclear cells and demonstrated atheroprotective activity.3
分子式:C10H19N3O4
分子量:245.26
溶剂:DMSO (25 mg/ml, with warming) Water (25 mg/ml)
性状:White solid
存储:-20°C
Activity (short version):Induces glutathione biosynthesis
Function / Pharmacology:Glycine-containing peptide which has been demonstrated to ameliorate nonalcoholic fatty liver disease (NAFLD). It improved body composition, and lowered circulating glucose, lipids, transaminases, proinflammatory cytokines and steatohepatitis in mice with established NASH.1 It dose-dependently attenuates NASH and fibrosis in mice as well as in nonhuman primates.2 It induced glutathione biosynthesis in mononuclear cells and demonstrated atheroprotective activity.3
